<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Global poliomyelitis eradication</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Global poliomyelitis eradication</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Global poliomyelitis eradication</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Modlin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H17939842"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Given the availability of an inexpensive oral polio vaccine (OPV) and the success of the Pan American Health Organization polio eradication program in the Americas, the World Health Assembly resolved in 1988 to eradicate polio globally by 2000 [<a href="#rid1">1</a>]. This goal has proven more challenging than originally foreseen, in part due to poor access to children in the remaining endemic areas, insecurity, deficiencies in program performance, and emergence of circulating oral poliovirus vaccine-derived polioviruses (cVDPV).</p><p>Nonetheless, great progress has been made; since 1988, the incidence of paralytic polio worldwide has been reduced by more than 1000-fold, and two of the three naturally occurring (wild-type) poliovirus serotypes no longer circulate. Wild-type 1 poliovirus (WPV1) circulation and disease are limited to only four countries: Pakistan, Afghanistan, Mozambique, and Malawi. However, the number of polio cases caused by type 2 cVDPVs in sub-Saharan Africa, Asia, Europe, and North America now exceed the incidence of WPV1 by an order of magnitude, creating a new front in the battle to eradicate poliomyelitis [<a href="#rid2">2,3</a>].</p><p>The long-term strategy of the Global Polio Eradication Initiative is to interrupt transmission of all wild-type and cVDPV viruses, phase out OPV use in a staged manner to reduce the risk of vaccine-associated paralytic poliomyelitis (VAPP) and new cVDPV outbreaks, and introduce inactivated <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> into the routine infant immunization schedule in all countries [<a href="#rid4">4</a>].</p><p>Issues related to polio eradication are reviewed here. Issues related to polio infection and routine polio vaccination are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5143.html" rel="external">"Poliomyelitis and post-polio syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/2695.html" rel="external">"Poliovirus vaccination"</a>.)</p><p class="headingAnchor" id="H17939848"><span class="h1">GLOBAL ERADICATION PARTNERSHIP</span><span class="headingEndMark"> — </span>The Global Polio Eradication Initiative partnership was launched in 1988 and is led by six organizations: the World Health Organization, the United States Centers for Disease Control and Prevention, the United Nations Children's Fund, Rotary International, the Bill and Melinda Gates Foundation, and Gavi, the vaccine alliance. The partnership includes many governmental and nongovernmental donors as well as the ministries of health of all affected nations who plan and carry out the program's initiatives, at an overall cost that exceeds $1 billion per year.</p><p class="headingAnchor" id="H17939855"><span class="h1">ERADICATION STRATEGIES</span><span class="headingEndMark"> — </span>The goal of the Global Polio Eradication Initiative (GPEI) is to interrupt transmission of naturally occurring (wild type) and vaccine-derived polioviruses by increasing population immunity via deployment of supplemental polio immunization activities (SIAs), in addition to routine infant immunization. The program depends on active surveillance for poliovirus-related acute flaccid paralysis (AFP) cases and detection of polioviruses in sewage (environmental surveillance) [<a href="#rid5">5,6</a>].</p><p>Until 2005, trivalent oral polio vaccine (tOPV) was used exclusively for routine immunization and in SIAs due to low cost, ease of administration by non-medical workers, and induction of mucosal immunity that reduces person-to-person and community poliovirus transmission. With the elimination of wild-type 2 poliovirus circulation in 1999, monovalent type 1 and type 3 vaccines (mOPV1 and mOPV3) and bivalent type 1 and 3 (bOPV) vaccine replaced tOPV for many SIAs conducted after 2005 due to superior immunogenicity against poliovirus types 1 and 3 [<a href="#rid7">7</a>].</p><p>Dose for dose, inactivated <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> (IPV) results in higher seroconversion rates than OPV in low-income settings, where the burden of enteric pathogens and tropical enteropathy reduces the efficacy of OPV [<a href="#rid8">8-10</a>]. However, IPV costs far more than OPV to produce, requires injection, and induces little or no intestinal immunity compared with OPV. For these reasons, IPV was not included in the program until 2015 prior to replacing tOPV with bOPV in 2016.</p><p class="headingAnchor" id="H17939862"><span class="h2">Routine immunization</span><span class="headingEndMark"> — </span>From the 1970s until 2016, most low- and middle-income countries used tOPV in their national childhood immunization programs following the World Health Organization (WHO) Expanded Program on Immunization (EPI) recommended schedule that specifies doses at birth and at 6, 10, and 14 weeks of age [<a href="#rid7">7</a>]. Most high-income countries continue to administer IPV in combination with other childhood vaccines, and some (mostly middle-income) countries deploy a mixed IPV-OPV schedule, including China, which now administers two IPV doses at two and three months of age and two bOPV doses at four months and four years of age [<a href="#rid11">11</a>].</p><p>The WHO Strategic Advisory Group of Experts (SAGE) on immunization recommended introduction of ≥1IPV doses into the EPI schedule in advance of the global, synchronized switch from tOPV to bOPV in April 2016 [<a href="#rid4">4,7</a>]. In most low-income countries, one dose of IPV is given at 14 weeks of age in addition to bOPV at birth and 6, 10, and 14 weeks of age.</p><p class="headingAnchor" id="H17939869"><span class="h2">Supplemental immunization activities</span><span class="headingEndMark"> — </span>Routine OPV immunization rates in many regions fall below the threshold required to interrupt poliovirus transmission; therefore, the GPEI relies on SIAs to raise population immunity to polio. SIAs (also known as National Immunization Days and Sub-National Immunization Days) deliver OPV via periodic, highly organized campaigns conducted door to door or at fixed sites within population centers [<a href="#rid5">5</a>]. Typically, a campaign is conducted over a few days and targets all persons of a specified age range (usually &lt;5 years) without regard to prior OPV immunization history. Since 2005, most SIAs have deployed mOPV and, more recently, bOPV. Until 2015, the GPEI conducted multiple bOPV and tOPV campaigns in 30 countries in Africa and Asia. The use of tOPV was discontinued in April 2016.</p><p>SIA quality is assessed through independent SIA monitoring protocols developed specifically for this purpose. SIAs are credited with interrupting poliovirus transmission worldwide, and programmatic successes in Africa and Asia are associated with improvements in SIA quality.</p><p class="headingAnchor" id="H982893934"><span class="h2">Surveillance</span><span class="headingEndMark"> — </span>Surveillance for poliomyelitis cases consists of detection of AFP cases in children and adolescents ≤15 years of age that are compatible with poliomyelitis [<a href="#rid12">12</a>]. Stool collected from AFP cases and close contacts within 14 days of onset are tested by cell culture in a regional Global Polio Laboratory Network laboratory for the presence of polioviruses and other enteroviruses. Poliovirus isolates are forwarded to reference laboratories for differentiation from oral <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> strains and further characterization. Only a small fraction of AFP cases is confirmed as polio by laboratory testing. In addition, the polio immunization status of every AFP case is recorded as an additional measure of population immunity.</p><p>Environmental surveillance for circulating wild-type and vaccine-derived polioviruses by periodic sampling of sewage effluents has been expanded in many high-risk areas to supplement AFP surveillance [<a href="#rid13">13</a>]. As fewer polio cases are detected by AFP surveillance, environmental surveillance activities are expanding in high-risk areas in Africa and Asia. Environmental surveillance has also proven valuable in other locations including Israel where WPV1 circulation was detected in the absence of poliomyelitis cases in 2013 [<a href="#rid14">14</a>].</p><p>In 2022, more than 100 genetically related type 2 Sabin vaccine viruses were isolated in sewer systems in London, New York state, and Israel [<a href="#rid15">15,16</a>]. In London and New York, these isolates were found in wastewater at multiple locations, and RNA sequencing classified some as cVDPV, confirming circulation of virulent polioviruses within these populations. As of November 2022, one AFP case has been identified during this outbreak, a young male residing in an under-immunized religious community in Rockland County, New York. Public health authorities responded by reviewing routine childhood immunization rates and encouraging IPV vaccination in affected populations.</p><p class="headingAnchor" id="H17939883"><span class="h2">Mop-up activities</span><span class="headingEndMark"> — </span>Mop-up campaigns are door-to-door SIAs that are carried out in focal areas where the virus is known or suspected to still be circulating. Priority areas include those where polio cases have been found over the previous three years and where access to healthcare is difficult. Other criteria include high population density, high population mobility, poor sanitation, and low routine immunization coverage.</p><p class="headingAnchor" id="H17939897"><span class="h1">CHALLENGES TO ERADICATION</span></p><p class="headingAnchor" id="H17939904"><span class="h2">Operational challenges</span><span class="headingEndMark"> — </span>Polio eradication has encountered numerous challenges, including variable commitment from national authorities, religious and cultural opposition, inadequate funding, poor campaign quality, surveillance gaps, and slow response to outbreaks [<a href="#rid17">17</a>]. In addition, extremist groups perpetrating violence against oral <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> (OPV) campaign workers in the remaining endemic areas deny access to hundreds of thousands of unvaccinated children.</p><p>In response, the Global Polio Eradication Initiative has improved supplementary immunization activity (SIA) planning, conduct, and monitoring, enhanced acute flaccid paralysis surveillance, and initiated environmental surveillance in high-risk areas. The program now integrates polio vaccination with routine immunization and other key health interventions, engaged government, traditional, and religious leaders at all levels, aggressively supported social mobilization teams to improve communication and advocacy locally, and introduced innovations designed to improve polio vaccine delivery, such as satellite global positioning system mapping and creation of immunization stations at transit points during population movements.</p><p class="headingAnchor" id="H970798629"><span class="h2">Low OPV efficacy</span><span class="headingEndMark"> — </span>The high burden of enteric pathogens can reduce seroconversion rates to less than 20 percent per OPV dose in some locations, leaving many children who have received multiple doses still susceptible to polio [<a href="#rid8">8,18,19</a>]. The elimination of naturally occurring type 2 polioviruses allowed for a partial solution to this problem: deployment of monovalent type 1 vaccine and bivalent types 1 and 3 vaccine in SIAs, which induces improved immune responses to type 1 and type 3 polioviruses by removing the interfering type 2 OPV viruses from the formulation [<a href="#rid20">20</a>]. The monovalent and bivalent formulations were instrumental in control of polio in India.</p><p class="headingAnchor" id="H921382812"><span class="h2">Vaccine-derived polioviruses</span><span class="headingEndMark"> — </span>Another challenge is circulation of vaccine-derived polioviruses (VDPVs); this was first recognized during an outbreak of poliomyelitis caused by a poliovirus derived from type 1 OPV vaccine occurring on the island of Hispaniola in 2000 [<a href="#rid21">21</a>]. The availability of viral genetic sequencing subsequently uncovered other circulating vaccine-derived poliovirus (cVDPV) outbreaks including extensive transmission of a type 2 VDPV virus in Egypt in the 1980s and periodic outbreaks caused by all three OPV types in multiple locations with low population immunity that permits ongoing person-to-person transmission [<a href="#rid21">21,22</a>]. (See  <a class="medical medical_review" href="/z/d/html/5143.html" rel="external">"Poliomyelitis and post-polio syndrome", section on 'Epidemiology'</a>.)</p><p>By convention, VDPV viruses diverge by ≥1.0 percent in the VP1 coding region compared with the parent OPV strains (≥0.6 percent for type 2), signifying ongoing transmission for ≥6 to 12 months. Since 2005, more than 80 percent of cases occurring during cVDPV outbreaks have been caused by type 2 OPV virus.</p><p>In addition, prolonged OPV virus replication in individuals with inherited B cell immunodeficiencies has rarely been associated with excretion of VDPV viruses (immunodeficiency-associated VDPVs) [<a href="#rid23">23</a>].</p><p>The recognition of VDPVs dictates that all OPV use will need to cease to achieve full polio eradication.</p><p class="headingAnchor" id="H1627579162"><span class="h1">PROGRESS</span><span class="headingEndMark"> — </span>Between 1988 and 2013, the annual global incidence of poliomyelitis fell by &gt;99.9 percent (from more than 350,000 cases to fewer than 1000 cases). Since 2012, all naturally occurring wild type cases have been caused by wild-type 1 poliovirus (WPV1). </p><p>India was certified by the World Health Organization in 2014 to have eradicated polio, a monumental achievement by a country that once harbored 85 percent of the global polio burden. In August 2020, the World Health Organization (WHO) declared Africa free of wild-type polio following four years without evidence of transmission. However, a new WPV1 case emerged in Malawi in November 2021, followed by eight cases in Mozambique, where circulation continues as of November 2022. The new African cases are genetically related to contemporary WPV1 viruses in Pakistan [<a href="#rid2">2,3,24</a>]. Worldwide, the annual number of reported WPV1 cases reached an historic low of only two cases in 2021 before rebounding in 2022 in the wake of the coronavirus pandemic.</p><p>Synchronized global withdrawal of oral <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> (OPV) began with removal of type 2 OPV from the trivalent vaccine in April 2016. Within two months, the prevalence of serotype 2 poliovirus in surveyed stool samples declined from 3.9 to 0.2 percent, and the detection rate in sewage samples declined from 71 to 13 percent [<a href="#rid25">25</a>]. Initially, as expected, a small number of VDPV2 outbreaks were identified and thought to have originated from tOPV2 use prior to the "switch" to bOPV [<a href="#rid3">3</a>].</p><p>However, ongoing use of monovalent (mOPV2) in response to VDPV2 outbreaks carries an increasing risk of seeding new VDPV2 outbreaks in the context of growing cohorts of infants and children without immunity to type 2 poliovirus. Between 2017 and November 2022, VDPV2 transmission has been reported in 46 countries causing more than 2600 acute flaccid paralysis cases. Sub-Saharan African countries are most affected, but AFP cases have also occurred in Syria, Afghanistan, Pakistan, Tajikistan, China, Philippines, and the United States. Some outbreaks have been controlled by deployment of mOPV2 vaccine in campaigns, but others continue to spread in susceptible populations representing a major challenge to the eradication program given the extent of spread and limited supply of mOPV2 vaccine [<a href="#rid3">3</a>]. In response, a novel OPV2 vaccine, designed to be genetically stable and less likely to generate VDPV2 viruses, received a WHO Emergency Use Listing in November 2020 and has since been deployed in 21 countries [<a href="#rid26">26,27</a>].</p><p class="headingAnchor" id="H363331420"><span class="h1">ENDGAME STRATEGY</span><span class="headingEndMark"> — </span>Because of an uncertain risk of circulating vaccine-derived poliovirus (cVDPV) reemergence from residual oral poliovirus type 2 circulation and from immunodeficient, long-term VDPV excretors, two inactivated <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> (IPV) doses at 14 weeks and 9 months of age have been added to the recommended Expanded Program on Immunization (EPI) schedule for oral polio vaccine (OPV)-using countries in addition to routine bivalent OPV (bOPV) doses at 6, 10, and 14 weeks of age [<a href="#rid28">28</a>]. This schedule provides seroconversion rates ≥97 percent for all three poliovirus serotype by nine months of age [<a href="#rid29">29-31</a>].</p><p>Conventional wisdom associates intestinal mucosal immunity, which reduces poliovirus excretion and person-to-person transmission, to OPV alone. However, studies in India have shown that IPV administered to children previously given OPV boosts both humoral neutralizing antibody and intestinal mucosal immunity as measured by bivalent OPV challenge [<a href="#rid32">32,33</a>].</p><p>Although virtually all high-income and many middle-income countries have eliminated polio with IPV alone, it is questionable whether similar success can be achieved in locations challenged by crowding and poor sanitation. Experience in Israel with prolonged detection of type 1 polioviruses in sewage effluents has generated substantial concern that IPV-induced intestinal immunity may not prevent silent transmission despite high immunization rates, and that infection could spread extensively before the first clinical case is detected [<a href="#rid34">34</a>].</p><p>Assuming success of the eradication program, all countries will rely on IPV alone to prevent poliovirus after total OPV withdrawal [<a href="#rid4">4</a>]. In April 2017, the World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) recommended that countries currently using bOPV plan to replace all OPV with 2 IPV doses at 14 weeks and approximately 9 months of age. Furthermore, SAGE recommended that IPV continue to be included in routine immunization schedules for a minimum of 10 years following certification of eradication. How long IPV vaccination will continue thereafter will be based on projected risk of recurrent polio, cost, and feasibility. The availability of affordable standalone IPV and IPV-containing combination vaccines will continue to guide the IPV market during this period.</p><p class="headingAnchor" id="H903112065"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/134422.html" rel="external">"Society guideline links: Polio"</a>.)</p><p class="headingAnchor" id="H17939925"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The Global Polio Eradication Initiative (GPEI) partnership is led by five organizations: the World Health Organization, the United States Centers for Disease Control and Prevention, the United Nations Children's Fund, Rotary International, the Bill and Melinda Gates Foundation, and Gavi, the vaccine alliance. (See <a class="local">'Global eradication partnership'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The GPEI deploys four strategies: routine infant immunization, supplementary immunization campaigns in many middle- and low-income countries, surveillance for acute flaccid paralysis, and mop-up campaigns. (See <a class="local">'Eradication strategies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The annual global incidence of poliomyelitis has fallen by &gt;99.9 percent from more than 350,000 cases when the GPEI was launched in 1988 to 361 cases, including circulating vaccine-derived poliovirus (cVDPV) cases, in 2021. (See <a class="local">'Progress'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two countries have never eliminated polio: Pakistan and Afghanistan. More than 40 countries have experienced reintroduction of wild-type 1 poliovirus (WPV1) polio from endemic areas or spread of cVDPV viruses because of low population immunity. (See <a class="local">'Challenges to eradication'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The GPEI "endgame" strategy calls for cessation of circulation of wild-type poliovirus and type 2 circulating vaccine-derived poliovirus, replacement of trivalent oral polio vaccine with bivalent oral polio vaccine for an interim period after April 2016, introduction of inactivated polio vaccine for routine childhood immunization, and eventual discontinuation of all oral <a class="drug drug_general" data-topicid="9787" href="/z/d/drug information/9787.html" rel="external">poliovirus vaccine</a> use once complete eradication of all types is certified by the World Health Organization. (See <a class="local">'Endgame strategy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">World Health Organization. Global eradication of poliomyelitis by the year 2000. Wkly Epidemiol Rec 1988; 63:161.</a></li><li><a class="nounderline abstract_t">Greene SA, Ahmed J, Datta SD, et al. Progress Toward Polio Eradication - Worldwide, January 2017-March 2019. MMWR Morb Mortal Wkly Rep 2019; 68:458.</a></li><li class="breakAll">World Health Organization GPEI. Wild Poliovirus Weekly Update. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx (Accessed on October 14, 2021).</li><li><a class="nounderline abstract_t">Garon J, Seib K, Orenstein WA, et al. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines 2016; 15:693.</a></li><li><a class="nounderline abstract_t">Wright PF, Kim-Farley RJ, de Quadros CA, et al. Strategies for the global eradication of poliomyelitis by the year 2000. N Engl J Med 1991; 325:1774.</a></li><li><a class="nounderline abstract_t">Asghar H, Diop OM, Weldegebriel G, et al. Environmental surveillance for polioviruses in the Global Polio Eradication Initiative. J Infect Dis 2014; 210 Suppl 1:S294.</a></li><li><a class="nounderline abstract_t">Polio vaccines: WHO position paper, January 2014. Wkly Epidemiol Rec 2014; 89:73.</a></li><li><a class="nounderline abstract_t">John TJ, Jayabal P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol 1972; 96:263.</a></li><li><a class="nounderline abstract_t">Sutter RW, Suleiman AJ, Malankar P, et al. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 2000; 343:767.</a></li><li><a class="nounderline abstract_t">Krishnan R, Jadhav M, John TJ. Efficacy of inactivated poliovirus vaccine in India. Bull World Health Organ 1983; 61:689.</a></li><li><a class="nounderline abstract_t">Zhao D, Ma R, Zhou T, et al. Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis - Beijing, China, 2014-2016. MMWR Morb Mortal Wkly Rep 2017; 66:1357.</a></li><li><a class="nounderline abstract_t">Mbaeyi C, Mohamed A, Owino BO, et al. Strengthening Acute Flaccid Paralysis Surveillance Through the Village Polio Volunteers Program in Somalia. Clin Infect Dis 2018; 67:941.</a></li><li><a class="nounderline abstract_t">Cowger TL, Burns CC, Sharif S, et al. The role of supplementary environmental surveillance to complement acute flaccid paralysis surveillance for wild poliovirus in Pakistan - 2011-2013. PLoS One 2017; 12:e0180608.</a></li><li><a class="nounderline abstract_t">Manor Y, Shulman LM, Kaliner E, et al. Intensified environmental surveillance supporting the response to wild poliovirus type 1 silent circulation in Israel, 2013. Euro Surveill 2014; 19:20708.</a></li><li><a class="nounderline abstract_t">Klapsa D, Wilton T, Zealand A, et al. Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Lancet 2022; 400:1531.</a></li><li><a class="nounderline abstract_t">Link-Gelles R, Lutterloh E, Schnabel Ruppert P, et al. Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater - New York, June-August 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1065.</a></li><li><a class="nounderline abstract_t">Roberts L. Polio endgame. Polio: The final assault? Science 2004; 303:1960.</a></li><li><a class="nounderline abstract_t">Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926.</a></li><li><a class="nounderline abstract_t">Grassly NC, Fraser C, Wenger J, et al. New strategies for the elimination of polio from India. Science 2006; 314:1150.</a></li><li><a class="nounderline abstract_t">Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010; 376:1682.</a></li><li><a class="nounderline abstract_t">Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296:356.</a></li><li><a class="nounderline abstract_t">Kew OM, Wright PF, Agol VI, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ 2004; 82:16.</a></li><li><a class="nounderline abstract_t">Macklin G, Diop OM, Humayun A, et al. Update on Immunodeficiency-Associated Vaccine-Derived Polioviruses - Worldwide, July 2018-December 2019. MMWR Morb Mortal Wkly Rep 2020; 69:913.</a></li><li class="breakAll">Global Polio Eradication Initiative. Polio Now. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx (Accessed on October 09, 2022).</li><li><a class="nounderline abstract_t">Blake IM, Pons-Salort M, Molodecky NA, et al. Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine. N Engl J Med 2018; 379:834.</a></li><li><a class="nounderline abstract_t">Yeh MT, Bujaki E, Dolan PT, et al. Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host Microbe 2020; 27:736.</a></li><li><a class="nounderline abstract_t">Sáez-Llorens X, Bandyopadhyay AS, Gast C, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet 2021; 397:27.</a></li><li class="breakAll">World Health Organization. Weekly Epidemiological Record 2020; 95:585. https://apps.who.int/iris/handle/10665/337100 (Accessed on November 07, 2022).</li><li><a class="nounderline abstract_t">Sutter RW, Bahl S, Deshpande JM, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet 2015; 386:2413.</a></li><li><a class="nounderline abstract_t">Asturias EJ, Bandyopadhyay AS, Self S, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet 2016; 388:158.</a></li><li><a class="nounderline abstract_t">Bandyopadhyay AS, Gast C, Rivera L, et al. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. Lancet Infect Dis 2021; 21:559.</a></li><li><a class="nounderline abstract_t">Jafari H, Deshpande JM, Sutter RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science 2014; 345:922.</a></li><li><a class="nounderline abstract_t">John J, Giri S, Karthikeyan AS, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet 2014; 384:1505.</a></li><li><a class="nounderline abstract_t">Kopel E, Kaliner E, Grotto I. Lessons from a public health emergency--importation of wild poliovirus to Israel. N Engl J Med 2014; 371:981.</a></li></ol></div><div id="topicVersionRevision">Topic 97003 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global eradication of poliomyelitis by the year 2000</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31120868" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Progress Toward Polio Eradication - Worldwide, January 2017-March 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31120868" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Progress Toward Polio Eradication - Worldwide, January 2017-March 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26751187" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Polio endgame: the global switch from tOPV to bOPV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1719418" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Strategies for the global eradication of poliomyelitis by the year 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25316848" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Environmental surveillance for polioviruses in the Global Polio Eradication Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24707513" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Polio vaccines: WHO position paper, January 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4342327" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10984564" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Trial of a supplemental dose of four poliovirus vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6605215" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy of inactivated poliovirus vaccine in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29240729" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis - Beijing, China, 2014-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509835" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Strengthening Acute Flaccid Paralysis Surveillance Through the Village Polio Volunteers Program in Somalia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28742803" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The role of supplementary environmental surveillance to complement acute flaccid paralysis surveillance for wild poliovirus in Pakistan - 2011-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24576473" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intensified environmental surveillance supporting the response to wild poliovirus type 1 silent circulation in Israel, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36243024" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980868" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater - New York, June-August 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15044779" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Polio endgame. Polio: The final assault?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1660184" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17110580" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : New strategies for the elimination of polio from India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20980048" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11896235" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15106296" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Circulating vaccine-derived polioviruses: current state of knowledge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32673297" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Update on Immunodeficiency-Associated Vaccine-Derived Polioviruses - Worldwide, July 2018-December 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32673297" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Update on Immunodeficiency-Associated Vaccine-Derived Polioviruses - Worldwide, July 2018-December 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30157398" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32330425" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33308427" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33308427" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26388534" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27212429" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33284114" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25146288" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Polio eradication. Efficacy of inactivated poliovirus vaccine in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018120" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25207764" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lessons from a public health emergency--importation of wild poliovirus to Israel.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
